|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colombo PE, Fabbro M, Theillet C, Bibeau
F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to
treatment in the primary management of epithelial ovarian cancer.
Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagaraj AB, Joseph P and DiFeo A: miRNAs
as prognostic and therapeutic tools in epithelial ovarian cancer.
Biomarkers Med. 9:241–257. 2015. View Article : Google Scholar
|
|
5
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Son B, Lee S, Youn HS, Kim EG, Kim W and
Youn BH: The role of tumor microenvironment in therapeutic
resistance. Oncotarget. 8:3933–3945. 2017.PubMed/NCBI
|
|
7
|
Liu Y and Cao X: Characteristics and
Significance of the Pre-metastatic Niche. Cancer Cell. 30:668–681.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu JS, Sheng SR, Liang XH and Tang YL: The
role of tumor microenvironment in collective tumor cell invasion.
Future Oncol. 13:991–1002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Richards KE, Zeleniak AE, Fishel ML, Wu J,
Littlepage LE and Hill R: Cancer-associated fibroblast exosomes
regulate survival and proliferation of pancreatic cancer cells.
Oncogene. 36:1770–1778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugiyama K, Kajiyama H, Shibata K, Yuan H,
Kikkawa F and Senga T: Expression of the miR200 family of microRNAs
in mesothelial cells suppresses the dissemination of ovarian cancer
cells. Mol Cancer Ther. 13:2081–2091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim J and Bae JS: Tumor-associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sica A, Larghi P, Mancino A, Rubino L,
Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P and Mantovani
A: Macrophage polarization in tumour progression. Semin Cancer
Biol. 18:349–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Zhang S, Yao J, Lowery FJ, Zhang
Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al:
Microenvironment-induced PTEN loss by exosomal microRNA primes
brain metastasis outgrowth. Nature. 527:100–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurahara H, Takao S, Maemura K, Mataki Y,
Kuwahata T, Maeda K, Sakoda M, Iino S, Ishigami S, Ueno S, et al:
M2-polarized tumor-associated macrophage infiltration of regional
lymph nodes is associated with nodal lymphangiogenesis and occult
nodal involvement in pN0 pancreatic cancer. Pancreas. 42:155–159.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reinartz S, Schumann T, Finkernagel F,
Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U,
Müller-Brüsselbach S, et al: Mixed-polarization phenotype of
ascites-associated macrophages in human ovarian carcinoma:
Correlation of CD163 expression, cytokine levels and early relapse.
Int J Cancer. 134:32–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lan C, Huang X, Lin S, Huang H, Cai Q, Wan
T, Lu J and Liu J: Expression of M2-polarized macrophages is
associated with poor prognosis for advanced epithelial ovarian
cancer. Technol Cancer Res Treat. 12:259–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takaishi K, Komohara Y, Tashiro H, Ohtake
H, Nakagawa T, Katabuchi H and Takeya M: Involvement of
M2-polarized macrophages in the ascites from advanced epithelial
ovarian carcinoma in tumor progression via Stat3 activation. Cancer
Sci. 101:2128–2136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carroll MJ, Kapur A, Felder M, Patankar MS
and Kreeger PK: M2 macrophages induce ovarian cancer cell
proliferation via a heparin binding epidermal growth factor/matrix
metalloproteinase 9 intercellular feedback loop. Oncotarget.
7:86608–86620. 2016.PubMed/NCBI
|
|
20
|
Iams WT and Lovly CM: Molecular pathways:
Clinical applications and future direction of insulin-like growth
factor-1 receptor pathway blockade. Clin Cancer Res. 21:4270–4277.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dyer AH, Vahdatpour C, Sanfeliu A and
Tropea D: The role of insulin-like growth factor 1 (IGF-1) in brain
development, maturation and neuroplasticity. Neuroscience.
325:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baserga R: The contradictions of the
insulin-like growth factor 1 receptor. Oncogene. 19:5574–5581.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin
G, Tang R, Dong J, Chen Y, Xu L, et al: A 3′-untranslated region
polymorphism in IGF1 predicts survival of non-small cell lung
cancer in a Chinese population. Clin Cancer Res. 16:1236–1244.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soulitzis N, Karyotis I, Delakas D and
Spandidos DA: Expression analysis of peptide growth factors VEGF
FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic
hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
|
|
25
|
Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H,
Zhou M, Pan C, Zhang J, Huang N, et al: IGF1/IGF1R/STAT3
signaling-inducible IFITM2 promotes gastric cancer growth and
metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pacher M, Seewald MJ, Mikula M, Oehler S,
Mogg M, Vinatzer U, Eger A, Schweifer N, Varecka R, Sommergruber W,
et al: Impact of constitutive IGF1/IGF2 stimulation on the
transcriptional program of human breast cancer cells.
Carcinogenesis. 28:49–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirakawa T, Yashiro M, Doi Y, Kinoshita H,
Morisaki T, Fukuoka T, Hasegawa T, Kimura K, Amano R and Hirakawa
K: Pancreatic fibroblasts stimulate the motility of pancreatic
cancer cells through IGF1/IGF1R sgnaling under hypoxia. PLoS One.
11:e01599122016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yaktapour N, Übelhart R, Schüler J, Aumann
K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, et
al: Insulin-like growth factor-1 receptor (IGF1R) as a novel target
in chronic lymphocytic leukemia. Blood. 122:1621–1633. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Terry KL, Tworoger SS, Gates MA, Cramer DW
and Hankinson SE: Common genetic variation in IGF1, IGFBP1 and
IGFBP3 and ovarian cancer risk. Carcinogenesis. 30:2042–2046. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Poljicanin A, Filipovic N, Vukusic Pusic
T, Soljic V, Caric A, Saraga-Babic M and Vukojevic K: Expression
pattern of RAGE and IGF-1 in the human fetal ovary and ovarian
serous carcinoma. Acta Histochem. 117:468–476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Torng PL, Lee YC, Huang CY, Ye JH, Lin YS,
Chu YW, Huang SC, Cohen P, Wu CW and Lin CT: Insulin-like growth
factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis
suppressor in ovarian endometrioid carcinoma. Oncogene.
27:2137–2147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koti M, Gooding RJ, Nuin P, Haslehurst A,
Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et
al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling
networks associated with chemotherapy resistance and treatment
response in high-grade serous epithelial ovarian cancer. BMC
Cancer. 13:5492013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu
KF and Chou CY: Circulating IGF system and treatment outcome in
epithelial ovarian cancer. Endocr Relat Cancer. 21:217–229. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y, Li Y, Zhang J, Zheng C, Zhu H, Yu H
and Fan L: Circulating insulin-like growth factor-1 level and
ovarian cancer risk. Cell Physiol Biochem. 38:589–597. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gianuzzi X, Palma-Ardiles G,
Hernandez-Fernandez W, Pasupuleti V, Hernandez AV and Perez-Lopez
FR: Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian
cancer risk: A systematic review and meta-analysis. Maturitas.
94:22–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin Y, Wei C, Liu Y, Qiu Y, Liu C and Guo
F: Selective ablation of tumor-associated macrophages suppresses
metastasis and angiogenesis. Cancer Sci. 104:1217–1225. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Remmele W and Stegner HE:
Immunhistochemischer Nachweis von Oestrogenrezeptoren (ER-ICA) in
Mammakarzinomen. Frauenarzt. 28:41–43. 1987.(In German).
|
|
39
|
Coward J, Kulbe H, Chakravarty P, Leader
D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J,
Vermeulen J, et al: Interleukin-6 as a therapeutic target in human
ovarian cancer. Clin Cancer Res. 17:6083–6096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koblish HK, Hansbury MJ, Bowman KJ, Yang
G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, et
al: Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase
potently suppress systemic tryptophan catabolism and the growth of
IDO-expressing tumors. Mol Cancer Ther. 9:489–498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Moughon DL, He H, Schokrpur S, Jiang ZK,
Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O and Wu L:
Macrophage blockade using CSF1R inhibitors reverses the vascular
leakage underlying malignant ascites in late-stage epithelial
ovarian cancer. Cancer Res. 75:4742–4752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, Chen JQ, Liu JL and Tian L:
Exosomes in tumor microenvironment: Novel transporters and
biomarkers. J Transl Med. 14:2972016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Goyne HE, Stone PJ, Burnett AF and Cannon
MJ: Ovarian tumor ascites CD14+ cells suppress dendritic
cell-activated CD4+ T-cell responses through IL-10 secretion and
indoleamine 2,3-dioxygenase. J Immunother. 37:163–169. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou H, Qian W, Uckun FM, Wang L, Wang YA,
Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, et al: IGF1 Receptor
targeted theranostic nanoparticles for targeted and image-guided
therapy of pancreatic cancer. ACS Nano. 9:7976–7991. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ukaji T, Lin Y, Banno K, Okada S and
Umezawa K: Inhibition of IGF-1-mediated cellular migration and
invasion by migracin A in ovarian clear cell carcinoma cells. PLoS
One. 10:e01376632015. View Article : Google Scholar : PubMed/NCBI
|
